Tenax Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tenax Therapeutics's earnings have been declining at an average annual rate of -9.4%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-9.4%
Earnings growth rate
57.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -296.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tenax Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -12 | 5 | 5 |
| 30 Jun 22 | 0 | -13 | 7 | 5 |
| 31 Mar 22 | 0 | -11 | 7 | 4 |
| 31 Dec 21 | 0 | -32 | 6 | 25 |
| 30 Sep 21 | 0 | -32 | 7 | 25 |
| 30 Jun 21 | 0 | -31 | 6 | 25 |
| 31 Mar 21 | 0 | -31 | 5 | 26 |
| 31 Dec 20 | 0 | -10 | 5 | 5 |
| 30 Sep 20 | 0 | -10 | 5 | 5 |
| 30 Jun 20 | 0 | -10 | 5 | 5 |
| 31 Mar 20 | 0 | -9 | 5 | 4 |
| 31 Dec 19 | 0 | -8 | 5 | 3 |
| 30 Sep 19 | 0 | -15 | 5 | 3 |
| 30 Jun 19 | 0 | -14 | 5 | 2 |
| 31 Mar 19 | 0 | -15 | 6 | 2 |
| 31 Dec 18 | 0 | -14 | 6 | 1 |
| 30 Sep 18 | 0 | -6 | 5 | 1 |
| 30 Jun 18 | 0 | -6 | 5 | 1 |
| 31 Mar 18 | 0 | -7 | 5 | 2 |
| 31 Dec 17 | 0 | -9 | 6 | 4 |
| 30 Sep 17 | 0 | -37 | 6 | 17 |
| 30 Jun 17 | 0 | -40 | 6 | 16 |
| 31 Mar 17 | 0 | -42 | 6 | 15 |
| 31 Dec 16 | 0 | -44 | 6 | 13 |
| 30 Sep 16 | 0 | -19 | 5 | 0 |
| 30 Jun 16 | 0 | -17 | 5 | 0 |
Quality Earnings: YBO is currently unprofitable.
Growing Profit Margin: YBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YBO is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.
Accelerating Growth: Unable to compare YBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: YBO has a negative Return on Equity (-296.16%), as it is currently unprofitable.